Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionmonooxygenase activity

MOXD2P MSMO1

4.86e-0411562GO:0004497
GeneOntologyMolecularFunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen

MOXD2P MSMO1

1.37e-0319462GO:0016705
GeneOntologyMolecularFunctionoxidoreductase activity

MOXD2P MSMO1

1.99e-0276662GO:0016491
GeneOntologyBiologicalProcessalcohol biosynthetic process

MOXD2P MSMO1

8.15e-0415462GO:0046165
GeneOntologyBiologicalProcessorganic hydroxy compound biosynthetic process

MOXD2P MSMO1

2.60e-0327762GO:1901617
GeneOntologyBiologicalProcessalcohol metabolic process

MOXD2P MSMO1

5.66e-0341262GO:0006066
Domain-

RLF ZNF462

1.23e-02679523.30.160.60
Domainzf-C2H2

RLF ZNF462

1.28e-0269352PF00096
DomainZnf_C2H2/integrase_DNA-bd

RLF ZNF462

1.28e-0269452IPR013087
DomainZINC_FINGER_C2H2_2

RLF ZNF462

1.58e-0277552PS50157
DomainZINC_FINGER_C2H2_1

RLF ZNF462

1.59e-0277752PS00028
DomainZnf_C2H2-like

RLF ZNF462

1.66e-0279652IPR015880
DomainZnf_C2H2

RLF ZNF462

1.70e-0280552IPR007087
DomainZnF_C2H2

RLF ZNF462

1.71e-0280852SM00355
Pubmed

Activity-dependent neuroprotective protein recruits HP1 and CHD4 to control lineage-specifying genes.

RLF ZNF462

6.66e-05746229795351
Pubmed

The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery.

RLF ZNF462 MSMO1

7.63e-0412036329180619
Cytoband7q34

MOXD2P ZC3HAV1

1.95e-04167627q34
CytobandEnsembl 112 genes in cytogenetic band chr7q34

MOXD2P ZC3HAV1

2.40e-0418562chr7q34
GeneFamilyZinc fingers C2H2-type|ZF class homeoboxes and pseudogenes

RLF ZNF462

8.96e-037184228
CoexpressionBROWNE_HCMV_INFECTION_4HR_UP

RLF ZC3HAV1

5.32e-055062M10161
CoexpressionGAO_ESOPHAGUS_25W_C3_FGFR1LOW_EPITHELIAL_CELLS

ZNF462 PHTF2

5.99e-055362M39138
CoexpressionBROCKE_APOPTOSIS_REVERSED_BY_IL6

MSMO1 PHTF2

4.56e-0414662M8244
CoexpressionKIM_WT1_TARGETS_8HR_UP

RLF ZC3HAV1

5.95e-0416762M8857
CoexpressionGSE36476_CTRL_VS_TSST_ACT_40H_MEMORY_CD4_TCELL_OLD_UP

RLF ZC3HAV1

8.35e-0419862M5299
CoexpressionGSE15930_NAIVE_VS_72H_IN_VITRO_STIM_TRICHOSTATINA_CD8_TCELL_DN

MSMO1 PHTF2

8.43e-0419962M3619
CoexpressionZHENG_FOXP3_TARGETS_IN_THYMUS_UP

PHTF2 ZC3HAV1

8.43e-0419962M1746
CoexpressionGSE15930_NAIVE_VS_24H_IN_VITRO_STIM_CD8_TCELL_DN

MSMO1 PHTF2

8.43e-0419962M3588
CoexpressionGSE18893_CTRL_VS_TNF_TREATED_TREG_24H_DN

RLF MSMO1

8.52e-0420062M7296
CoexpressionZHENG_FOXP3_TARGETS_IN_THYMUS_UP

PHTF2 ZC3HAV1

8.52e-0420062MM1033
CoexpressionGSE9037_CTRL_VS_LPS_4H_STIM_IRAK4_KO_BMDM_DN

PHTF2 ZC3HAV1

8.52e-0420062M5811
CoexpressionGSE360_DC_VS_MAC_L_DONOVANI_DN

MSMO1 ZC3HAV1

8.52e-0420062M5176
CoexpressionGSE43955_10H_VS_60H_ACT_CD4_TCELL_WITH_TGFB_IL6_UP

MSMO1 PHTF2

8.52e-0420062M9686
CoexpressionGSE2770_TGFB_AND_IL4_VS_IL4_TREATED_ACT_CD4_TCELL_2H_DN

ZNF462 MSMO1

8.52e-0420062M6080
CoexpressionGSE3039_NKT_CELL_VS_B1_BCELL_DN

MSMO1 PHTF2

8.52e-0420062M6433
CoexpressionGSE27786_LIN_NEG_VS_MONO_MAC_DN

MSMO1 ZC3HAV1

8.52e-0420062M4798
CoexpressionAtlasdev gonad_e12.5_F_GermCellOvary_Oct_k-means-cluster#1_top-relative-expression-ranked_1000

ZNF462 ZC3HAV1

1.92e-053052gudmap_dev gonad_e12.5_F_GermCellOvary_Oct_k1_1000
CoexpressionAtlasDevelopingGonad_e12.5_epididymis_emap-29139_top-relative-expression-ranked_500

RLF ZNF462 ZC3HAV1

6.60e-0540353gudmap_developingGonad_e12.5_epididymis_500
CoexpressionAtlasDevelopingGonad_e18.5_ovary_emap-12283_top-relative-expression-ranked_1000

RLF PHTF2 ZC3HAV1

4.64e-0477853gudmap_developingGonad_e18.5_ovary_1000
CoexpressionAtlasDevelopingGonad_e16.5_ovary_emap-9563_top-relative-expression-ranked_1000

RLF PHTF2 ZC3HAV1

4.94e-0479553gudmap_developingGonad_e16.5_ovary_1000
CoexpressionAtlasDevelopingGonad_e18.5_epididymis_emap-13166_top-relative-expression-ranked_1000

RLF ZNF462 MSMO1

5.01e-0479953gudmap_developingGonad_e18.5_epididymis_1000
CoexpressionAtlasDevelopingGonad_e12.5_epididymis_emap-29139_top-relative-expression-ranked_1000

RLF ZNF462 ZC3HAV1

5.14e-0480653gudmap_developingGonad_e12.5_epididymis_1000
CoexpressionAtlasdev gonad_e12.5_F_GermCellOvary_Oct_top-relative-expression-ranked_1000

ZNF462 PHTF2 ZC3HAV1

5.45e-0482253gudmap_dev gonad_e12.5_F_GermCellOvary_Oct_1000
CoexpressionAtlasfacebase_RNAseq_e10.5_OlfacPit_2500_K0

ZNF462 MSMO1 PHTF2

7.74e-0492653facebase_RNAseq_e10.5_OlfacPit_2500_K0
ToppCellControl-T_cells-Tregs|Control / group, cell type (main and fine annotations)

PHTF2 ZC3HAV1

2.08e-0416962e1e0983f31ec81b3fad5f9c6140d17f03f81a5dc
ToppCellCOVID-19-T_cells-Tregs|COVID-19 / group, cell type (main and fine annotations)

PHTF2 ZC3HAV1

2.39e-0418162534659cf754326c6a73c0daa30e9d610612a0292
ToppCellLPS_only|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

RLF ZC3HAV1

2.50e-0418562a72ccb147ca505880e2da8f6a70b9d570464a691
ToppCell10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8|GI_small-bowel / Manually curated celltypes from each tissue

RLF ZC3HAV1

2.58e-0418862ab9b725d6e0cdab8e9ddda6dee09e14730e9a578
ToppCellrenal_medulla_nuclei-Adult_normal_reference-Epithelial-Collecting_tubule_epithelial_cell-kidney_collecting_duct_principal_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

PHTF2 ZC3HAV1

2.60e-0418962fc88c51ace7d883c01617f3f9b5fab70cc91cc09
ToppCellChildren_(3_yrs)-Immune-T_lymphocyte-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor

PHTF2 ZC3HAV1

2.60e-0418962df30478b288084a1bd48f660409dcc784040897c
ToppCellChildren_(3_yrs)-Immune-T_lymphocyte|Children_(3_yrs) / Lineage, Cell type, age group and donor

PHTF2 ZC3HAV1

2.72e-0419362b9769b45125d2244afe53f9f71c92c04ddccf980
ToppCellChildren_(3_yrs)-Immune-T_lymphocyte-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor

PHTF2 ZC3HAV1

2.74e-04194623d6f2d190dd50804afea299957cc44c2bb756134
ToppCellcritical-Lymphoid-Treg|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls

PHTF2 ZC3HAV1

2.80e-0419662861665912eb0538b083d3eee77190925b3a43c24
ToppCell10x5'-Liver-Lymphocytic_T_CD4|Liver / Manually curated celltypes from each tissue

PHTF2 ZC3HAV1

2.83e-04197624891111894b741555f549deec6af8006376d9358
ToppCellAT2_cells-Donor_04|World / lung cells shred on cell class, cell subclass, sample id

ZNF462 MSMO1

2.86e-04198628a1f984e46f4fa5be33027b9dbaa2ca060a2245d
ToppCellBronchial-NucSeq-Immune_Lymphocytic-T-T_CD4-T_reg|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

PHTF2 ZC3HAV1

2.86e-04198627608f67959e1cda7b10e57fd3af2f96216ebe7e9
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC-OPC|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

ZNF462 MSMO1

2.89e-0419962e60ecbb8fa7bcd3e2ce7d78f6efb2cfd1fd77698
ToppCellmild-CD4+_Tcm|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

PHTF2 ZC3HAV1

2.89e-041996206c8a0e39f7a33736548f04a5e2263334c8541cf
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

ZNF462 MSMO1

2.89e-0419962333056c2abe9724efeab542c0365fcfe4eff8f18
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC-OPC-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

ZNF462 MSMO1

2.89e-041996219a97e27a4758e794ce7246d295e112b47931a48
ToppCellSmart-start-Cell-Wel_seq-Non-neoplastic-Glial-Neuronal-OPC-OPC-F|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

ZNF462 MSMO1

2.91e-0420062ad777683adeb2ce45ade570386235e311fa7ea2d
ToppCellParenchymal-10x3prime_v2-Immune_Myeloid-Myeloid|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations

ZNF462 PHTF2

2.91e-0420062cc8368665bc6bb7c4f39632ccff07ceaa98a7b65
ToppCellParenchymal-10x3prime_v2-Immune_Myeloid-Myeloid-Megakaryocyte|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations

ZNF462 PHTF2

2.91e-04200620d76b006d8e8b32174e65e400acd0674354b962c
DrugFendiline hydrochloride [13636-18-5]; Up 200; 11.4uM; MCF7; HT_HG-U133A

MSMO1 ZC3HAV1

7.59e-04164627188_UP
DrugCycloheximide [66-81-9]; Down 200; 14.2uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

8.06e-04169623464_DN
DrugCephaeline dihydrochloride heptahydrate [6487-30-5]; Down 200; 6uM; HL60; HT_HG-U133A

MSMO1 ZC3HAV1

8.25e-04171622429_DN
DrugCephaeline dihydrochloride heptahydrate [6487-30-5]; Down 200; 6uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

8.25e-04171625247_DN
DrugDequalinium dichloride [522-51-0]; Down 200; 7.6uM; HL60; HT_HG-U133A

RLF MSMO1

8.54e-04174621276_DN
DrugCephaeline dihydrochloride heptahydrate [6487-30-5]; Down 200; 6uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

9.03e-04179624651_DN
Drug17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A_EA

PHTF2 ZC3HAV1

9.03e-04179621005_UP
DrugPuromycin dihydrochloride [58-58-2]; Down 200; 7.4uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

9.13e-04180625310_DN
DrugPyrvinium pamoate [3546-41-6]; Down 200; 3.4uM; HL60; HT_HG-U133A

RLF PHTF2

9.23e-04181622957_DN
DrugCycloheximide [66-81-9]; Down 200; 14.2uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

9.23e-04181626220_DN
DrugLycorine hydrochloride [2188-68-3]; Down 200; 12.4uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

9.33e-04182623808_DN
DrugClemastine fumarate [14976-57-9]; Up 200; 8.6uM; MCF7; HT_HG-U133A

MSMO1 PHTF2

9.44e-04183627443_UP
DrugEmetine dihydrochloride [316-42-7]; Down 200; 7.2uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

9.44e-04183624243_DN
DrugThiostrepton [1393-48-2]; Up 200; 2.4uM; HL60; HT_HG-U133A

PHTF2 ZC3HAV1

9.54e-04184622462_UP
DrugAmoxicillin [26787-78-0]; Down 200; 11uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

9.64e-04185622620_DN
Druggeldanamycin; Up 200; 1uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

9.74e-04186621228_UP
DrugAnisomycin [22862-76-6]; Down 200; 15uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

9.85e-04187626764_DN
Drugthapsigargin; Down 200; 0.1uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

1.02e-03190627053_DN
DrugStrophantine octahydrate [11018-89-6]; Down 200; 5.4uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

1.02e-03190626680_DN
DrugF0447-0125; Up 200; 10uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

1.02e-03190626429_UP
DrugQuercetine dihydrate [6151-25-3]; Down 200; 11.8uM; HL60; HT_HG-U133A

PHTF2 ZC3HAV1

1.03e-03191622499_DN
DrugNoscapine [128-62-1]; Down 200; 9.6uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

1.04e-03192622745_DN
DrugPentolinium bitartrate [52-62-0]; Down 200; 7.4uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

1.05e-03193627375_DN
DrugCP-645525-01 [287190-82-3]; Up 200; 10uM; MCF7; HT_HG-U133A

MSMO1 PHTF2

1.06e-03194627522_UP
Drugnordihydroguaiaretic acid; Up 200; 1uM; MCF7; HT_HG-U133A_EA

MSMO1 ZC3HAV1

1.06e-03194621061_UP
DrugRetrorsine [480-54-6]; Down 200; 11.4uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

1.06e-03194622784_DN
Drug(R) -Naproxen sodium salt [26159-34-2]; Down 200; 15.8uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

1.06e-03194626794_DN
DrugIopamidol [60166-93-0]; Up 200; 5.2uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

1.06e-03194627189_UP
DrugPrimaquine diphosphate [63-45-6]; Down 200; 8.8uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

1.06e-03194624263_DN
DrugDihydroergotamine tartrate [5989-77-5]; Down 200; 3uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

1.07e-03195624502_DN
DrugDesipramine hydrochloride [58-28-6]; Up 200; 13.2uM; MCF7; HT_HG-U133A

MSMO1 PHTF2

1.07e-03195623212_UP
DrugAtropine sulfate monohydrate [5908-99-6]; Down 200; 5.8uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

1.07e-03195622761_DN
Drug(+) -Levobunolol hydrochloride [47141-41-3]; Down 200; 12.2uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

1.07e-03195626635_DN
DrugProtriptyline hydrochloride [1225-55-4]; Down 200; 13.4uM; HL60; HT_HG-U133A

PHTF2 ZC3HAV1

1.07e-03195623119_DN
DrugMefexamide hydrochloride [3413-64-7]; Down 200; 12.6uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

1.08e-03196622121_DN
DrugTrihexyphenidyl-D,L Hydrochloride [58947-95-8]; Down 200; 11.8uM; HL60; HT_HG-U133A

PHTF2 ZC3HAV1

1.08e-03196622158_DN
DrugDemecarium bromide [56-94-0]; Up 200; 5.6uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

1.08e-03196626269_UP
Drug6-Hydroxytropinone [5932-53-6]; Down 200; 25.8uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

1.08e-03196627346_DN
Drugchlorpropamide; Up 200; 100uM; MCF7; HG-U133A

MSMO1 PHTF2

1.08e-0319662144_UP
DrugFolic acid [59-30-3]; Down 200; 9uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

1.09e-03197622783_DN
DrugHydrocotarnine hydrobromide [5985-00-2]; Down 200; 13.2uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

1.09e-03197622765_DN
DrugVitamin K2 [11032-49-8]; Down 200; 9uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

1.09e-03197623798_DN
DrugProstaglandin E1; Down 200; 10uM; MCF7; HT_HG-U133A

RLF ZC3HAV1

1.10e-03198626576_DN
Drug2-propylpentanoic acid; Up 200; 50uM; MCF7; HT_HG-U133A_EA

PHTF2 ZC3HAV1

1.10e-03198621002_UP
Drugrottlerin; Down 200; 10uM; MCF7; HT_HG-U133A_EA

PHTF2 ZC3HAV1

1.10e-0319862914_DN
DrugDinoprost trometamol [38362-01-5]; Down 200; 8.4uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

1.11e-03199626308_DN
DrugMolsidomine [25717-80-0]; Down 200; 16.6uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

1.11e-03199625426_DN
DrugRauwolscine hydrochloride [6211-32-1]; Down 200; 10.2uM; MCF7; HT_HG-U133A

PHTF2 ZC3HAV1

1.11e-03199622778_DN
Druggenistein; Up 200; 10uM; PC3; HT_HG-U133A

PHTF2 ZC3HAV1

1.13e-03200621235_UP
DrugAcetaldehyde

PHTF2 ZC3HAV1

1.37e-0322162ctd:D000079
Diseasecomparative body size at age 10, self-reported

ZNF462 ZC3HAV1

2.92e-0342062EFO_0009819
Diseaseblood urea nitrogen measurement

ZNF462 PHTF2

3.37e-0345262EFO_0004741

Protein segments in the cluster

PeptideGeneStartEntry
HHKRIYKYIHKVHHE

MSMO1

161

Q15800
YKYIHKVHHEFQAPF

MSMO1

166

Q15800
EKHHIYKFEPKLVYH

MOXD2P

221

A6NHM9
RKSHHYKKHYPNEDA

PHTF2

361

Q8N3S3
YILNKYHKPFHCIHK

RLF

1301

Q13129
HGTLEKLKIHYEKYH

ZNF462

1586

Q96JM2
KKYKLSEIHHLHPEY

ZC3HAV1

726

Q7Z2W4